<DOC>
	<DOCNO>NCT01949415</DOCNO>
	<brief_summary>House Dust Mites ( HDM ) arachnids infest bedding , carpet , upholstered furniture fabric . Like many allergen , exposure HDMA sensitise patient associate poor lung function , great medication requirement asthma symptom well chronic rhinosinusitis symptom . In contrast allergen , evidence HDMA lead development asthma , addition exacerbate pre-existing asthma HDM-sensitised patient . ToleroMune House Dust Mite ( TM-HDM ) develop treatment HDM allergy . Study TH002 evaluate efficacy , safety tolerability TM-HDM . This study identify cellular , proteomic genetic biomarkers efficacy TM-HDM treatment TH002 study participant</brief_summary>
	<brief_title>An Optional Investigation Biomarkers Efficacy</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Previously randomise study TH002 , complete study receive either placebo 12 nmol dose TH002 . Subjects receive allergen peptide immunotherapy last 12 month ( TMHDM )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>House Dust Mite</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>ToleroMune</keyword>
</DOC>